Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
Public ClinicalTrials.gov record NCT02561273. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I/II trial studies the side effects and best dose of lenalidomide when given together with combination chemotherapy and to see how well they work in treating patients with newly diagnosed stage II-IV peripheral T-cell non-Hodgkin's lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lenalidomide may stop the growth of peripheral T-cell non-Hodgkin's lymphoma by blocking the growth of new blood vessels necessary for cancer growth. Giving combination chemotherapy with lenalidomide may be a better treatment for peripheral T-cell non-Hodgkin's lymphoma.
Study identification
- NCT ID
- NCT02561273
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 54 participants
Conditions and interventions
Conditions
- Anaplastic Large Cell Lymphoma, ALK-Negative
- Anaplastic Large Cell Lymphoma, ALK-Positive
- Hepatosplenic T-Cell Lymphoma
- Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Stage II Angioimmunoblastic T-cell Lymphoma
- Stage II Enteropathy-Associated T-Cell Lymphoma
- Stage III Angioimmunoblastic T-cell Lymphoma
- Stage III Enteropathy-Associated T-Cell Lymphoma
- Stage IV Angioimmunoblastic T-cell Lymphoma
- Stage IV Enteropathy-Associated T-Cell Lymphoma
Interventions
- Autologous Hematopoietic Stem Cell Transplantation Procedure
- Cyclophosphamide Drug
- Doxorubicin Hydrochloride Drug
- Etoposide Drug
- Laboratory Biomarker Analysis Other
- Lenalidomide Drug
- Peripheral Blood Stem Cell Transplantation Procedure
- Prednisone Drug
- Vincristine Sulfate Drug
Procedure · Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 27, 2015
- Primary completion
- Oct 31, 2019
- Completion
- Oct 31, 2020
- Last update posted
- Dec 12, 2023
2015 – 2020
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Comprehensive Cancer Center | Duarte | California | 91010 | — |
| Stanford Cancer Institute | Palo Alto | California | 94304 | — |
| University of Colorado Cancer Center, Anschutz Cancer Pavilion | Aurora | Colorado | 80045 | — |
| Emory University/Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02561273, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 12, 2023 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02561273 live on ClinicalTrials.gov.